UK markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.79 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1602
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.36%)
     
  • BTC-GBP

    34,176.08
    -1,036.70 (-2.94%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.68 (+1.06%)
     
  • CRUDE OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD FUTURES

    1,844.00
    +20.00 (+1.10%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

The Worldwide Meningococcal Vaccine Industry is Expected to Reach $4.5 Billion by 2026 - ResearchAndMarkets.com

·4-min read

The "Global Meningococcal Vaccine Market By Brand, By Type, By Age Group, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Meningococcal Vaccine Market size is expected to reach $4.5 billion by 2026, rising at a market growth of 8.5% CAGR during the forecast period.

Meningococcal meningitis is a bacterial infection that is caused by gram-negative bacteria, Neisseria meningitides that includes a spectrum of infections such as bacteremia (meningococcemia), meningitis, and bacteremia pneumonia.

The meningococcal disease is very rare but is highly fatal, if left untreated, up to 50% of the patients die or get some serious complications thereafter. In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics. The disease is transmitted from an infected person through direct contact with droplets of the throat or respiratory secretions, asymptomatic carriers can also capable of transmitting infection.

There is an increasing prevalence of various types of bacteria that cause meningococcal meningitis. The most common type of meningitis causing bacteria are A, B, C, W, Y, and type X that was more lately reported in Africa, continue to underline the criticality of more effective vaccine of meningococcal to be available in the coming years.

Over the past few decades, cases of meningitis have been increased and are one of the key factors likely to drive the market for meningococcal vaccines. According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year. The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth. For example, "Defeating meningitis by 2030" was introduced in 2018 at the World Health Assembly by Eastern Mediterranean and African regions. This program is focused to develop a strategic roadmap for the prevention of meningitis by prioritizing research and improved control activities.

Companies Profiled

  • GlaxoSmithKline PLC (GSK)

  • Pfizer, Inc.

  • Sanofi S.A.

  • Walvax Biotechnology Co., Ltd.

  • Bio-Manguinhos (Oswaldo Cruz Foundation)

  • Bio-Med Pvt. Ltd.

  • Chongqing Zhifei Biological Products Co., Ltd.

  • Hualan Biological Engineering, Inc.

  • Incepta Pharmaceuticals Ltd.

  • Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)

Unique Offerings from the Publisher

  • Exhaustive coverage

  • Highest number of market tables and figures

  • Subscription based model available

  • Guaranteed best price

  • Assured post sales research support with 10% customization free

Key Topics Covered:

Chapter 1. Market Scope & Methodology

1.1 Market Definition

1.2 Objectives

1.3 Market Scope

1.4 Segmentation

1.4.1 Global Meningococcal Vaccine Market, by Brand

1.4.2 Global Meningococcal Vaccine Market, by Type

1.4.3 Global Meningococcal Vaccine Market, by Age Group

1.4.4 Global Meningococcal Vaccine Market, by Geography

1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction

2.1.1 Overview

2.1.2 Market composition and scenario

2.2 Key Factors Impacting the Market

2.2.1 Market Drivers

2.2.2 Market Restraints

Chapter 3. Recent Developments in Meningococcal Vaccine Market

Chapter 4. Global Meningococcal Vaccine Market by Brand

4.1 Global Bexsero Market by Region

4.2 Global Trumenba Market by Region

4.3 Global Nimenrix Market by Region

4.4 Global Menactra Market by Region

4.5 Global Menveo Market by Region

4.6 Global Other Brands Market by Region

Chapter 5. Global Meningococcal Vaccine Market by Type

5.1 Global Bivalent Market by Region

5.2 Global Quadrivalent Market by Region

5.3 Global Other Types Market by Region

Chapter 6. Global Meningococcal Vaccine Market by Age Group

6.1 Global Children (2 years & above) and Adults Market by Region

6.2 Global Infants(0 to 2 years) Market by Region

Chapter 7. Global Meningococcal Vaccine Market by Region

7.1 North America Meningococcal Vaccine Market

7.2 Europe Meningococcal Vaccine Market

7.3 Asia Pacific Meningococcal Vaccine Market

7.4 LAMEA Meningococcal Vaccine Market

Chapter 8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/n5ula4

View source version on businesswire.com: https://www.businesswire.com/news/home/20210416005294/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900